OrthoPediatrics Corp. (NASDAQ:KIDS) CFO Sells $160,172.98 in Stock

OrthoPediatrics Corp. (NASDAQ:KIDS) CFO Fred Hite sold 6,443 shares of the firm’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total value of $160,172.98. Following the transaction, the chief financial officer now directly owns 207,989 shares in the company, valued at approximately $5,170,606.54. The trade was a 3.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

OrthoPediatrics Stock Down 1.1 %

OrthoPediatrics stock opened at $25.15 on Thursday. The stock has a 50 day moving average of $24.79 and a two-hundred day moving average of $25.53. OrthoPediatrics Corp. has a twelve month low of $21.02 and a twelve month high of $35.99. The stock has a market capitalization of $610.82 million, a price-to-earnings ratio of -20.45 and a beta of 1.22. The company has a current ratio of 7.17, a quick ratio of 3.68 and a debt-to-equity ratio of 0.19.

OrthoPediatrics (NASDAQ:KIDS) last issued its quarterly earnings results on Tuesday, March 4th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.04. The firm had revenue of $52.67 million during the quarter, compared to the consensus estimate of $51.16 million. OrthoPediatrics had a negative return on equity of 5.78% and a negative net margin of 15.00%. During the same period last year, the company earned ($0.23) earnings per share. As a group, research analysts expect that OrthoPediatrics Corp. will post -0.93 earnings per share for the current year.

Analyst Upgrades and Downgrades

KIDS has been the topic of a number of research reports. Needham & Company LLC restated a “buy” rating and set a $42.00 price target on shares of OrthoPediatrics in a research note on Wednesday, March 5th. Truist Financial lowered their target price on shares of OrthoPediatrics from $28.00 to $25.00 and set a “hold” rating on the stock in a research report on Wednesday, December 18th. Finally, Stifel Nicolaus reduced their price target on shares of OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, March 5th.

Institutional Trading of OrthoPediatrics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Millennium Management LLC acquired a new stake in OrthoPediatrics in the fourth quarter valued at about $9,798,000. Point72 Asset Management L.P. purchased a new position in shares of OrthoPediatrics during the 4th quarter worth approximately $7,450,000. Wasatch Advisors LP lifted its holdings in shares of OrthoPediatrics by 47.2% in the 4th quarter. Wasatch Advisors LP now owns 696,318 shares of the company’s stock valued at $16,141,000 after buying an additional 223,217 shares during the period. Wellington Management Group LLP boosted its stake in shares of OrthoPediatrics by 20.2% in the fourth quarter. Wellington Management Group LLP now owns 1,061,299 shares of the company’s stock valued at $24,601,000 after buying an additional 178,078 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in OrthoPediatrics by 29.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 671,968 shares of the company’s stock worth $15,576,000 after acquiring an additional 152,681 shares during the period. Hedge funds and other institutional investors own 69.05% of the company’s stock.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.